Trials / Conditions / Astrocytoma, Grade IV

Astrocytoma, Grade IV

24 registered clinical trials studyying Astrocytoma, Grade IV — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4 NCT07459101	Sunnybrook Health Sciences Centre	N/A
Active Not Recruiting	A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent M NCT06614855	James Markert, MD	Phase 1
Recruiting	Study of Olutasidenib and Temozolomide in HGG NCT06161974	Rigel Pharmaceuticals	Phase 2
Recruiting	T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma NCT06157541	Queensland Institute of Medical Research	Phase 1 / Phase 2
Withdrawn	The Addition of Chloroquine to Chemoradiation for Glioblastoma, NCT02432417	Maastricht Radiation Oncology	Phase 2
Not Yet Recruiting	Coaching for Coping in Glioblastoma Patients and Caregivers and Its Association With Compliance to TTFields NCT06017063	University Hospital Tuebingen	N/A
Recruiting	Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astr NCT05789394	Mayo Clinic	Phase 1
Recruiting	SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) NCT05303519	Nuvation Bio Inc.	Phase 3
Withdrawn	CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type NCT05218408	Celularity Incorporated	Phase 1 / Phase 2
Recruiting	The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 220 NCT06118723	Jasper Gerritsen	—
Completed	Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma NCT04757662	Washington University School of Medicine	Phase 1
Completed	BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and NCT05375318	Juan M Garcia-Gomez	—
Terminated	Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM NCT04489420	Celularity Incorporated	Phase 1
Completed	ALBATROSS Study: International Multicenter Study for Prospective Validation of Imaging Biomarkers Calculated a NCT05229198	Juan M Garcia-Gomez	—
Recruiting	The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients. NCT03861299	Jasper Gerritsen	N/A
Withdrawn	Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas NCT03956706	Northwell Health	N/A
Completed	Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma NCT03072134	Northwestern University	Phase 1
Completed	A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent NCT02766699	Engeneic Pty Limited	Phase 1
Completed	Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme NCT02465268	University of Florida	Phase 2
Completed	Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma NCT02709226	National Cancer Institute (NCI)	Phase 1
Terminated	Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma NCT02510950	Washington University School of Medicine	Phase 1
Completed	DC Migration Study for Newly-Diagnosed GBM NCT02366728	Mustafa Khasraw, MBChB, MD, FRCP, FRACP	Phase 2
Completed	Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Ca NCT01240460	Sanofi	Phase 1
Withdrawn	Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM NCT00943462	Centre hospitalier de l'Université de Montréal (CHUM)	—